Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Weight at least 40 kg~* A diagnosis of partial epilepsy according to the International League Against Epilepsy's Classification of Epileptic Seizures. Diagnosis should have been established by clinical history and an electroencephalogram (EEG) that is consistent with localization related epilepsy; normal interictal EEGs will be allowed provided that the subject meets the other diagnosis criterion (ie, clinical history)~* Have uncontrolled partial seizures despite having been treated with at least 1 AED within approximately the last 2 years~* During the 8-week baseline period, subjects must have at least 8 partial seizures including only simple partial seizures with motor component, complex partial seizures, or secondarily generalized seizures without a seizure-free interval of greater than 25 days any time during the 8 weeks baseline. Subjects must have at least 3 of these partial seizures during each of the two consecutive 4-week segments of the baseline period~* Currently on stable antiepileptic treatment regimen.~Exclusion Criteria:~* A history of nonepileptic or psychogenic seizures~* Presence of only nonmotor simple partial seizures or primary generalized epilepsies~* Presence or previous history of Lennox-Gastaut syndrome~* An active CNS infection, demyelinating disease, degenerative neurologic disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results~* Any clinically significant psychiatric illness, psychological, or behavioral problems that, in the opinion of the Investigator, would interfere with the subject's ability to participate in the study~* History of alcoholism, drug abuse, or drug addiction within the past 2 years~* History of status epilepticus within 3 months of Visit 1~* A yes answer to Question 1 or 2 of the C-SSRS (Baseline/Screening version) Ideation Section in the past 6 months or a yes answer to any of the Suicidal Behavior Questions in the past 2 years~* More than 1 lifetime suicide attempt~* Participation in any other trials involving an investigational product or device within 30 days of screening (or longer, as required by local regulations)~* A history of any previous exposure to YKP3089

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- YKP3089 Low Dose (Type: EXPERIMENTAL): YKP3089 Low Dose
- YKP3089 Medium Dose (Type: EXPERIMENTAL): YKP3089 Medium Dose
- YKP3089 High Dose (Type: EXPERIMENTAL): YKP3089 High Dose

Based on this trial design, predict the completion outcome and termination type (if applicable).